New drug CS231295 enters first human trial for tough cancers
Disease control
Not yet recruiting
This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …
Phase: PHASE1 • Sponsor: ThalassaX Therapeutics United States Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC